Skip to main content
Erschienen in: Virchows Archiv 3/2020

27.02.2020 | Original Article

Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays

verfasst von: Takehiro Shiraishi, Eiji Shinto, Ines P. Nearchou, Hitoshi Tsuda, Yoshiki Kajiwara, Takahiro Einama, Peter D. Caie, Yoji Kishi, Hideki Ueno

Erschienen in: Virchows Archiv | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Mesothelin (MSLN) is a cell surface glycoprotein present in many cancer types. Its expression is generally associated with an unfavorable prognosis. This study examined the prognostic significance of MSLN expression in different areas of individual colorectal cancers (CRCs) using tissue microarrays (TMAs) by enrolling 314 patients with stage II (T3–T4, N0, M0) CRCs. Using formalin-fixed paraffin-embedded tissue blocks from patients, TMA blocks were constructed. Tissue core specimens were obtained from submucosal invasive front (Fr-sm), subserosal invasive front (Fr-ss), central area (Ce), and rolled edge (Ro) of each tumor. Using these four-point TMA sets, MSLN expression was immunohistochemically surveyed. The area-specific prognostic significance of MSLN expression was evaluated. A deep learning convolutional neural network algorithm was used for imaging analysis and evaluating our judgment’s objectivity. MSLN staining ratio was positively correlated between the manual and machine-learning analyses (r = 0.71). The correlation coefficient between Ro and Ce, Ro and Fr-sm, and Ro and Fr-ss was r = 0.63, r = 0.54, and r = 0.61, respectively. Disease-specific survival curves for the MSLN-positive and MSLN-negative groups in Fr-sm, Fr-ss, and Ro were significantly different (five-year survival rates 88.1% and 95.5% (P = 0.024), 85.0 and 96.2% (P = 0.0087), 87.8 and 95.5% (P = 0.051), and 77.9 and 95.8% (P = 0.046) for Fr-sm, Fr-ss, Ce, and Ro, respectively). The analysis performed using area-specific four-point TMAs clearly demonstrated that MSLN expression in stage II CRC was relatively homogeneous within tumors. Additionally, high MSLN expression showed or tended to show unfavorable prognostic significance regardless of the tumor area.
Literatur
12.
16.
19.
Zurück zum Zitat Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. Wiley-Liss, New York, pp 73–76 Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. Wiley-Liss, New York, pp 73–76
20.
Zurück zum Zitat Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K, Japanese Society for Cancer of the C, Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) (2015) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20:207–239. https://doi.org/10.1007/s10147-015-0801-zCrossRefPubMedPubMedCentral Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K, Japanese Society for Cancer of the C, Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) (2015) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20:207–239. https://​doi.​org/​10.​1007/​s10147-015-0801-zCrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRef
25.
Zurück zum Zitat Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Control 19:716–722CrossRef Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Control 19:716–722CrossRef
26.
Zurück zum Zitat Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105:195–199. https://doi.org/10.1002/jso.22024CrossRefPubMed Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S (2012) Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105:195–199. https://​doi.​org/​10.​1002/​jso.​22024CrossRefPubMed
30.
Zurück zum Zitat Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671. https://doi.org/10.1200/JCO.2008.20.8397CrossRefPubMed Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671. https://​doi.​org/​10.​1200/​JCO.​2008.​20.​8397CrossRefPubMed
31.
Zurück zum Zitat Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417. https://doi.org/10.1056/NEJMoa0805019CrossRefPubMed Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417. https://​doi.​org/​10.​1056/​NEJMoa0805019CrossRefPubMed
32.
Zurück zum Zitat Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. https://doi.org/10.1200/JCO.2007.14.9930CrossRefPubMed Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. https://​doi.​org/​10.​1200/​JCO.​2007.​14.​9930CrossRefPubMed
38.
Zurück zum Zitat Ono M, Tsuda H, Yunokawa M, Yonemori K, Shimizu C, Tamura K, Kinoshita T, Fujiwara Y (2015) Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. Breast Cancer 22:141–152. https://doi.org/10.1007/s12282-013-0464-4CrossRefPubMed Ono M, Tsuda H, Yunokawa M, Yonemori K, Shimizu C, Tamura K, Kinoshita T, Fujiwara Y (2015) Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. Breast Cancer 22:141–152. https://​doi.​org/​10.​1007/​s12282-013-0464-4CrossRefPubMed
41.
Zurück zum Zitat Bui MM, Asa SL, Pantanowitz L, Parwani A, van der Laak J, Ung C, Balis U, Isaacs M, Glassy E, Manning L (2019) Digital and computational pathology: bring the future into focus. J Pathol Inform 10:10PubMedCentral Bui MM, Asa SL, Pantanowitz L, Parwani A, van der Laak J, Ung C, Balis U, Isaacs M, Glassy E, Manning L (2019) Digital and computational pathology: bring the future into focus. J Pathol Inform 10:10PubMedCentral
Metadaten
Titel
Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays
verfasst von
Takehiro Shiraishi
Eiji Shinto
Ines P. Nearchou
Hitoshi Tsuda
Yoshiki Kajiwara
Takahiro Einama
Peter D. Caie
Yoji Kishi
Hideki Ueno
Publikationsdatum
27.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 3/2020
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-020-02775-y

Weitere Artikel der Ausgabe 3/2020

Virchows Archiv 3/2020 Zur Ausgabe

Neu im Fachgebiet Pathologie